Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies pentostatin and donor lymphocyte infusion in preventing graft
rejection in patients who have undergone donor stem cell transplant. Giving pentostatin and
an infusion of the donor's T cells (donor lymphocyte infusion) after a donor stem cell
transplant may stop the patient's immune system from rejecting the donor's stem cells. The
donated stem cells may replace the patient's immune cells and help destroy any remaining
cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can
also make an immune response against the body's normal cells. Giving pentostatin before donor
lymphocyte infusion may stop this from happening.